News
ABBV
--
0.00%
--
Is AbbVie (ABBV) A Good Stock To Buy?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus...
Insider Monkey · 4h ago
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA
AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.
Zacks · 14h ago
Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval
Zacks.com · 16h ago
Global Sterile Injectable Drugs Market Growth to be Propelled by Increasing R&D Initiatives to Witness Considerable GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 20h ago
Best Dividend Stocks In 2021? 4 To Watch This Week
StockMarket.com · 1d ago
AbbVie (ABBV) Stock Moves -1.23%: What You Should Know
Zacks.com · 1d ago
As markets tumble, here are some low volatility, high-dividend yield stocks that Wall Street likes
For investors searching for yield amidst September's market volatility, safer stocks that pay hefty dividends could be a good choice.
CNBC.com · 1d ago
BRIEF-Alvotech Says FDA Defers Action on Application For Proposed Humira Biosimilar
reuters.com · 1d ago
AbbVie Reports Submission Of Regulatory Application To FDA For Risankizumab-rzaa For Treatment Of Patients 16 Years+ With Moderate To Severe Crohn's Disease
- In three pivotal Phase 3 studies, risankizumab-rzaa demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy[1],[2],[3] - The overall safety findings
In three pivotal Phase 3 studies, risankizumab-rzaa demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy[1],[2],[3] - The overall safety findings · 1d ago
BRIEF-Abbvie Inc Submits Regulatory Application To FDA For RISANKIZUMAB-RZAA (SKYRIZI)
reuters.com · 1d ago
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleu...
PR Newswire · 1d ago
Sunflower Bank, N.A. Buys S&P 500 ETF TRUST ETF, Procter & Gamble Co, JPMorgan ...
GuruFocus News · 1d ago
Tay-Sachs Disease Drugs Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2030
Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region.
AmericaNewsHour · 1d ago
AbbVie Seeks FDA Approval for Crohn's Disease Treatment Candidate
MT Newswires · 1d ago
Global Sterile Injectable Drugs Market to Witness Considerable growth throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 1d ago
DiGeorge Syndrome Drug Market Propelled by Increased Patient Pool and R&D Initiatives to Witness Substantial GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the DiGeorge syndrome drug market in terms of market segmentation by therapy type, route of administration, end-user, and by region.
AmericaNewsHour · 1d ago
Cramer: Using Short-Term Moves to Tweak Your Portfolio
Whether the news is good or bad, you can take advantage of it if you understand why you're involved in a stock in the first place.
TheStreet.com · 2d ago
Calamos Growth and Income Portfolio Buys AbbVie Inc, Sells Fortive Corp, Vertex Pharmaceuticals ...
GuruFocus News · 3d ago
5 Berkshire Hathaway Stocks in Downtrends
GuruFocus News · 4d ago
AbbVie Slumps On New FDA Order For Arthritis Drug — Is It A Buy Or A Sell?
Is AbbVie stock a buy or a sell after the FDA said arthritis drug, Rinvoq, would need to include a warning label?
Investor's Business Daily · 4d ago
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about AbbVie through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.